Technology offers new solutions in reaching and activating people



But how do they fit into routine care provision?



7 out of 10 physicians recognise the potential of digital technology

Patients would use digital services especially if physicians recommend or prescribe them.

Bertelsmann-Stiftung in Hartmannbund-Magazin, 03/2018

A large proportion of physicians would strongly recommend health apps if they would have been assessed previously by Independent organizations. Berlin Chemie in Ärztezeitung online, 08/2018

The usage of digital technologies could save up to € 34 billion a year in the german healthcare system.

McKinsey & Company, 09/2018

The progress of rapid technological change is leading to a variety of new digital and other health innovations



Traditional ways of thinking and conventual pattern stop the necessary ability and agility to innovate

ji

The effects of implementing an innovation are difficult to quantify, which leads to a negative attitude against them



The fundamental problems are the translation-gaps 1 and 2 and 3

T1 refers to the conversion of knowledge from basic science research into a potential clinical product for testing on human subjects.

T2 tends to refer to the process of converting promising interventions in clinical research into guidelines. Each phase of translational research is associated with a set of research activities which contribute to temporal expenditure and expenses and therefore to implementation lags.

Scientific findings don't find their way into practice

easily! Decision makers do not only need scientific evidence, but need to confront evidence with theory, ideologies, local context, micro politics, barriers etc. (Greenhalgh & Wieringa 2011). The process needs to facilitate evidence-informed decision making (Armstrong R 2011) -> knowledge translation



Based on Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J Royal Society Medicine 2011)

Reasons why translating & implementing fails

Many assessments of **Decision-makers** innovations do not include do not have any direct investigations in enough expertise acceptance and feasibility to make informed and thus provide an and conscientious insufficient basis for decisions decision-making Many approaches **do** Many approaches **do** not have enough insight not follow the into the decisionmaking psychology of underlie incentive the targeted population structure and and therefore are not therefore are rejected accepted as expected Many technologies have The healthcare market great potential, but **no** is flooded with digital mature business model concepts and ideas, which results in a lack and therefore fail to establish themselves on of transparency and the market high complexity

Our Solution – a comprehensive assessment to make decisions easier.

Development of a Online Database on relevant and assessed health or system related applications and solutions

Offering a Supplementary Service to give advice and support the implementation of innovations Use of Data Analytics to carry out real-world evaluations and to create epidemiological and econometric models

11.

Our Toolbox

COMPILING EVIDENCE

Through us you will get an understanding of agile intervention studies and theirs specific utility parameters in the context of digital health

ASSESSING QUALITY

With us, you identify relevant innovations that are already successful or show great potential for success

GAUGING FEASIBILITY

We estimate how realistic an integration of an innovation is in the daily routine of care

COMPARE INNOVATIONS

We create structured overviews of innovations in comparison to each other and with respect to parameters such as effectiveness and feasibility

EVALUATE ACCEPTANCE & PRACTICAL BENEFIT

We investigate the level of acceptance and actual benefit of the innovation by examining the existing incentive and health care structure in real-world-setting

GENERATE A BUSINESS CASE

We help to measure the added value of a use case considering strategic and economic aspects

PLANNING IMPLEMENTATION

We design pathways and flowcharts to support the change management and realisation of implementation

CONDUCT REAL-WOLRD-EVALUATIONS

We use health service utilisation data for our evaluations that has been released for research purposes

SCALING

Based on pilot testing we are able to create epidemiological and econometric models and prognose the effects on short-, medium- and long-term



Our Service in three phases

Quality Assessment

Piloting & Acceptance Evaluation

Epidemiological and Econometric Modelling We provide information for conscientious decisionmaking. Our quality assessment is based on latest researches in the field of Digital Health.

We assess the acceptance and practical benefit of innovations by examining the existing incentive and health care structure in the realworld.

We use data analytics to evaluate pilot projects and develop epidemiological and econometric models as a basis for new business models.

Quality Assessment: Our Meta Catalogue of Criteria to evaluate Innovations

Clarify current state of research and gauge feasibility of a specific digital health field.

Assessing promising innovations

on the basis of existing evidence, feasibility, functionality, quality and benefits as well as aspects such as security/certification, privacy, usability and pricing models.

Using a rating score to **compare** different innovations of the same application context. The values are weighted differently depending on the requirements of the implementation setting.

	_					_	
-				_	_	Page 1	_
internet at the set of	-				1010		Ţ.
Careful State of Society					-		21
November November Nationalise Salation		022	and the second s		2	an lang i	in and a second
Normalia Malanda Anada Malanda Malanda Malanda		11-1					ta tage
			Annual and a second sec		-		
		00.00					
			Sector of the se				
			Sector of the se				

and then be along our imperior before the particular

not published yet ...





Piloting & Acceptance Evaluation

Consultations with the medical advisory board→ Identification of partners for pilot studies (short cycle – 2 weeks)



Supporting the pilot study: Declarations of consent, data usage, installations if required, structured survey of relevant data on acceptance and usage, documentation



Focus group with stakeholders during a quality circle



Editing the progress report (including survey of relevant EBM, payment and care concepts)

Epidemiological and Econometric Modelling



The analysis is based on health service utilisation data as well as evidence data from RCTs. It shows the **probability of cost savings and reasons for potential cost savings** in the system.

Table 4. Sensitivity of selected model to different take-up rates. Mean (95%CI). 10% "w&t" rate

Model	P	rob. Cost savi	ing	Savings in thousands of euros			
	(*s.4	- setting	He av	1-1-1-1-12 ¹⁹ -1-18 ¹⁹	Sec. at	5.2 C 15	
30%	$= \mathcal{T} ^{2}$	49.97.94	(\$107.%)	R: (50000)	1. M. S.S.	Sec. 84	
40%	1999	14	· Neces	Sec. 14	a court	1 5 46 15 455	
50%	ŧ.	8.5		- Annie wohen	State of	any soft	
70%	20	w.	h	- Marchaeller	-	ser	
80%	N	17	b-	NAN BURN	esere in	Sugar det	
90%	1. 4. 100 S. 104	liveration and	and a lar	ise her some with	and the second	the second second	

Illustration 3: Sensitivity analysis of different rates of program completion ...not published yet

Why OptiMedis?

Years of experience in innovations of the health sector Database of > 100 assessed digital and innovative applications and solutions

Extensive expertise in developing and implementing innovative health care models Interdisciplinary team of professionals in medicine, health sciences, business administration, IT and social science Our presence in related OptiMedis companies outside of Germany and participation in numerous EU projects create an exchange of knowledge and experiences on an international level

Our Pricing Structure



Quality Assessment

- Compiling evidence
- Assessing quality
- Gauging feasibility
- Comparing innovations

man-days x number of innovations €



Pilot Implementation

- Generating a Business Case
- Investigating level of acceptence
- Assessing actual benefit
- Testing real-world-evidence



Scaling

- Creating epidemiological & econometric models
- Prognosing impact on system level
- Developing business model



```
man-days x €
```







OptiMedis AG

Tel.:+49 40 22621149-0E-Mail:innovation@optimedis.deWeb:www.optimedis.deAddresse:Burchardstraße 17, 20095 Hamburg